Harnessing cell-engineering delivery platform to develop small molecules, vaccines, and cell and gene therapies. Platform based on Flow Electroporation™ Technology, with ability to transfect primary cells, stem cells and cell lines with minimal cell disturbance and transfection efficiencies routinely >90% for a variety of cell types.
Healthcare/Medical Diagnostics & Research
US - South Atlantic
Phase l or ll, Pre-Clinical Stage
Cell Therapy, Gene editing, Gene Therapy
22 Firstfield Road
Gaithersburg, MD 20878
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Top 10 Holders of MaxCyte, Inc.
Top 10 Holders of MaxCyte, Inc. TEMP
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by